F S&P 500
5,044.50 -63.00 (-1.23%) F Dow Jones
38,235.00 -445.00 (-1.15%) F Nasdaq
17,379.00 -285.50 (-1.62%) E-mini Russell 2000 Index Futur
1,983.60 -23.20 (-1.16%) Petróleo
82.88 +0.07 (+0.08%) Oro
2,343.50 +5.10 (+0.22%)
Codexis, Inc. (CDXS)
Antes de la apertura del mercado:
Codexis, Inc.
200 Penobscot Drive
Redwood City, CA 94063
United States
650 421 8100
https://www.codexis.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 174
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Stephen George Dilly MBBS, Ph.D. | President, CEO & Director | 753.61k | N/D | 1960 |
| Mr. Kevin Norrett M.B.A., M.S. | Chief Operating Officer | 507.28k | N/D | 1973 |
| Ms. Margaret Fitzgerald J.D. | Chief Legal and Compliance Officer, General Counsel & Secretary | 300.03k | N/D | 1971 |
| Mr. Sriram Ryali M.B.A. | Chief Financial Officer | N/D | N/D | 1982 |
| Carrie McKim | Director of Investor Relations | N/D | N/D | N/D |
| Ms. Karen Frechou-Armijo | Senior VP & Head of Human Resources | N/D | N/D | N/D |
| Dr. Stefan Lutz Ph.D. | Senior Vice President of Research | N/D | N/D | N/D |
| Mr. Robert Sato M.B.A., Ph.D. | Senior Vice President of Pharmaceutical Development, Quality & Regulatory | N/D | N/D | N/D |
Descripción
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Codexis, Inc. a partir del 1 de abril de 2024 es 5. Las puntuaciones principales son Auditoría: 4; Junta: 3; Derechos del accionista: 8; Compensación: 7.
